Geode Capital Management
CLDI icon

Geode Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Geode Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Buy
63,019
+21,090
+50% +$15.8K ﹤0.01% 4473
2025
Q4 		$49.1K Buy
41,929
+12,334
+42% +$18.1K ﹤0.01% 4240
2025
Q3 		$45K Buy
29,595
+10,214
+53% +$43.4K ﹤0.01% 4316
2025
Q2 		$53.5K Sell
19,381
-1,612
-8% -$7.83K ﹤0.01% 4201
2025
Q1 		$143K Buy
20,993
+7,658
+57% +$87.3K ﹤0.01% 3936
2024
Q4 		$184K Buy
13,335
+10,034
+304% +$188K ﹤0.01% 3930
2024
Q3 		$45.2K Buy
+3,301
New +$57.4K ﹤0.01% 4284
2024
Q2 		– Sell
-893
Closed -$60.5K – 4592
2024
Q1 		$60.5K Buy
893
+41
+5% +$4.19K ﹤0.01% 4283
2023
Q4 		$154K Buy
+852
New +$229K ﹤0.01% 4029

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Geode Capital Management's CLDI Position: Q1 2026 in Review

Geode Capital Management increased its Calidi Biotherapeutics (CLDI) stake by 50% in Q1 2026, buying an estimated $15.8K and bringing the position to 63,019 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #4473.

Geode Capital Management first reported a position in CLDI in Q4 2023 and has held it in 9 quarters since. The position peaked at $184K in Q4 2024. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Geode Capital Management held 63,019 shares of Calidi Biotherapeutics worth $15K as of Q1 2026.
  • Geode Capital Management bought 21,090 Calidi Biotherapeutics shares in Q1 2026, an estimated $15.8K.
  • Calidi Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4473 holding.
  • Geode Capital Management first reported a position in Calidi Biotherapeutics in Q4 2023 and has held it in 9 quarters since.
  • Geode Capital Management's Calidi Biotherapeutics position peaked at $184K in Q4 2024.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.